Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 OriginOil Inc. (OTC/QB: OOIL), developer ... to clean up large quantities of water, announced today ... reported on the launch of the company's CLEAN-FRAC™ industrial ... by partner STW Resources . , Immediately upon ... day (bpd) and achieved a 99.8% reduction in Turbidity ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... partnership focusing on commercializing market-relevant biohealth innovations and increasing ... , announced today that venture capitalist, Tania ... a strategic advisor. Dr. Fernandez will be a member ... Fund, which will provide up to $50 million in ...
(Date:9/30/2014)... September 30, 2014 iLab Solutions announced ... Benchmarking study which focuses on core facility operations, ... core managers face today. , In its 4th year ... of note is the year-over-year decrease in the percentage ... appear to be feeling the constraints of this trend. ...
(Date:9/30/2014)... The custom stainless steel fabrication company ... 2014. The Boston Area Chapter of ISPE (International Society ... event for Wed., Oct. 1 at Gillette Stadium Clubhouse ... largest in ISPE Boston’s long history, with more than ... expected. , HOLLOWAY AMERICA President David Simpson is ...
Breaking Biology Technology:OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... technologys sake. And yet a visiting space alien that is ... for believing thats what most of us are doing. We ... the technology and almost none of our energy into assessing ... From the way we allocate our energy and attention, it ...
... MADISON, Wis. — With the University of Wisconsin System ... of creating two separate statewide networks, Gov. Jim Doyle ... efforts. , ,"It's more sensible for taxpayers to have ... spokesperson Dan Leistikow. , ,Initial discussions last year about ...
... a new product, behave just like parents jumping in ... of the incubation wing is often replaced by a ... Dilbertish style revolution. Objects do fly, even though they ... Everyone shares the excitement and all fights are well ...
Cached Biology Technology:Why are you buying technology? 2Why are you buying technology? 3Governor tells UW to scrap network plans 2Naming that thing... again? 2Naming that thing... again? 3Naming that thing... again? 4
(Date:9/30/2014)... Institutes of Health (NIH) awarded Lawrence Livermore National ... electrode array system that will enable researchers to ... resolution and scale. , LLNL,s grant-funded project is ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... our understanding of the human mind and uncover ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... Calif. Researchers at Sandia National Laboratories will use ... high-throughput assays as part of a multiproject, $34 ... (ARPA-E) aimed at developing advanced biocatalyst technologies that ... transportation. The ARPA-E program is Reducing Emissions ...
... scientific team has discovered a gene associated with a ... variant may be an actual cause of this form ... children. "Because asthma is a complex disease, with ... recurrent asthma occurring between ages two and six," said ...
... OVERVIEW: Straight from Stockholm: Randy Schekman, Ph.D., ... New Orleans after receiving the 2013 Nobel Prize in ... 2,500 poster presentations about the latest research on cellular ... cell interactions and the proverbial much, much more. ...
Cached Biology News:Converting natural gas to liquid transportation fuels via biological organisms 2Converting natural gas to liquid transportation fuels via biological organisms 3Novel gene variant found in severe childhood asthma 2
...
TNM-FH Insect Medium 1 liter...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Biology Products: